Despite expectations born a decade ago, there are only a few successes in stratified medicine up to now and its implementation proves to be challenging in many aspects. Numerous factors are considered in making decisions. Indeed the pharmaceutical sector becomes increasingly aware of the potential benefits of stratified medicine but it seems inhibited by uncertainties. In addition to the above mentioned obstacles in research, the regulatory framework, intellectual property issues, the uncertain impact on the market and doubtful commercial advantages contribute to create an unclear landscape that seems to prevent the main stakeholders to clearly move forward. .
